S
Salut Brunet
Researcher at Autonomous University of Barcelona
Publications - 307
Citations - 11856
Salut Brunet is an academic researcher from Autonomous University of Barcelona. The author has contributed to research in topics: Transplantation & Hematopoietic stem cell transplantation. The author has an hindex of 56, co-authored 306 publications receiving 10622 citations. Previous affiliations of Salut Brunet include Hospital General Universitario Gregorio Marañón & University of Valencia.
Papers
More filters
Journal ArticleDOI
Causes and prognostic factors of remission induction failure in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and idarubicin.
Javier de la Serna,Pau Montesinos,Edo Vellenga,Chelo Rayon,Ricardo Parody,Angel Leon,Jordi Esteve,Juan Bergua,Gustavo Milone,Guillermo Deben,Concha Rivas,Marcos González,Mar Tormo,Joaquín Díaz-Mediavilla,José González,Silvia Negri,Elena Amutio,Salut Brunet,Bob Löwenberg,Miguel A. Sanz +19 more
TL;DR: Clinical relevant information is furnished that might be useful for designing more appropriately risk-adapted treatment protocols aimed at reducing the considerable problem of induction mortality in APL.
Journal ArticleDOI
Interleukin-3 receptor alpha chain (CD123) is widely expressed in hematologic malignancies.
Luz Muñoz,Josep F. Nomdedeu,Olga Lopez,Maria J. Carnicer,Mar Bellido,Anna Aventin,Salut Brunet,Jorge Sierra +7 more
TL;DR: Data show high expression of IL-3 receptor a chain in hematologic malignancies and CD123 is expressed with a characteristic pattern in cases of hairy cell leukemia, which could be applied to the study of minimal residual disease in acute leukemia.
Journal ArticleDOI
Peripheral T-cell lymphomas: Initial features, natural history, and prognostic factors in a series of 174 patients diagnosed according to the R.E.A.L. Classification
Armando López-Guillermo,Joan Cid,Antonio Salar,Aurelio López,Carlos Montalbán,J. M. Castrillo,Marcos González,Josep-Maria Ribera,Salut Brunet,Javier García-Conde,A. Fernandez de Sevilla,Francesc Bosch,Montserrat E +12 more
TL;DR: PTCL have adverse prognostic features at diagnosis, respond poorly to therapy and have short survival, with no sustained remission, and ALCL constitutes a subgroup which responds better to Therapy and has a longer survival.
Journal ArticleDOI
Risk-adapted treatment of acute promyelocytic leukemia based on all-trans retinoic acid and anthracycline with addition of cytarabine in consolidation therapy for high-risk patients: further improvements in treatment outcome.
Miguel A. Sanz,Pau Montesinos,Chelo Rayon,Alexandra Holowiecka,Javier de la Serna,Gustavo Milone,Elena de Lisa,Salut Brunet,Vicente Rubio,José M. Ribera,Concha Rivas,Isabel Krsnik,Juan Bergua,José González,Joaquín Díaz-Mediavilla,R Rojas,Félix Manso,Gert J. Ossenkoppele,José D. González,Bob Löwenberg +19 more
TL;DR: The lower dose of mitoxantrone resulted in a significant reduction of toxicity and hospital stay while maintaining the antileukemic activity, and the combination of ATRA, idarubicin, and cytarabine for high-risk acute promyelocytic leukemia significantly reduced the relapse rate in this setting.
Journal ArticleDOI
Differentiation syndrome in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline chemotherapy: characteristics, outcome, and prognostic factors
Pau Montesinos,Juan Bergua,Edo Vellenga,Chelo Rayon,Ricardo Parody,Javier de la Serna,Angel Leon,Jordi Esteve,Gustavo Milone,Guillermo Deben,Concha Rivas,Marcos González,Mar Tormo,Joaquín Díaz-Mediavilla,José D. González,Silvia Negri,Elena Amutio,Salut Brunet,Bob Löwenberg,Miguel A. Sanz +19 more
TL;DR: An analysis of the incidence, characteristics, prognostic factors, and outcome of 739 APL patients treated with ATRA plus idarubicin in 2 consecutive trials indicated that a WBC count greater than 5 x 10(9)/L and an abnormal serum creatinine level correlated with an increased risk of developing severe DS.